Goflikicept not checked
R-Pharm International, LLC · RPH-104
FollowEvery change as it happens, and a Monday email
Trials
5 active
13 in total
Targets
—
None known yet
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial”In the company’s words, NCT05673902 on ClinicalTrials.gov
- Tested for
- Familial Mediterranean Fever (3 trials), FMF (3 trials), Idiopathic Recurrent Pericarditis, Still Disease
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.”In the company’s words, NCT05673902 on ClinicalTrials.gov
- Other names
- RPH-104 · Arcerix
Other drugs for Idiopathic Recurrent Pericarditis
Coming up3
- 14 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jan 2026 | Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis | |
| Phase 3Not yet recruiting | 14 Dec 2027 | Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease | |
| Phase 3Not yet recruiting | May 2029 | Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever | |
| Phase 2Active, not recruiting | Jan 2025 | Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine | |
| Phase 2Recruiting | Dec 2028 | Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever | |
| Phase 3Withdrawn | Aug 2025 | Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) | |
| Phase 2/3Completed | 10 Jul 2020 | Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) | |
| Phase 2/3Completed | 24 Jan 2022 | Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis | |
| Phase 2/3Suspended | May 2027 | Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis | |
| Phase 2Completed | 3 Nov 2021 | Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction | |
| Phase 2Withdrawn | Aug 2023 | Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome | |
| Phase 1Completed | Jun 2017 | Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects | |
| Phase 1Completed | 27 Feb 2025 | Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026